Arginase Inhibition Reverses Monocrotaline-Induced Pulmonary Hypertension

Pulmonary hypertension (PH) is a heterogeneous disorder associated with a poor prognosis. Thus, the development of novel treatment strategies is of great interest. The enzyme arginase (Arg) is emerging as important player in PH development. The aim of the current study was to determine the expression of ArgI and ArgII as well as the effects of Arg inhibition in a rat model of PH. PH was induced in 35 Sprague–Dawley rats by monocrotaline (MCT, 60 mg/kg as single-dose). There were three experimental groups: sham-treated controls (control group, n = 11), MCT-induced PH (MCT group, n = 11) and MCT-induced PH treated with the Arg inhibitor Nω-hydroxy-nor-l-arginine (nor-NOHA; MCT/NorNoha group, n = 13). ArgI and ArgII expression was determined by immunohistochemistry and Western blot. Right ventricular systolic pressure (RVPsys) was measured and lung tissue remodeling was determined. Induction of PH resulted in an increase in RVPsys (81 ± 16 mmHg) compared to the control group (41 ± 15 mmHg, p = 0.002) accompanied by a significant elevation of histological sum-score (8.2 ± 2.4 in the MCT compared to 1.6 ± 1.6 in the control group, p < 0.001). Both, ArgI and ArgII were relevantly expressed in lung tissue and there was a significant increase in the MCT compared to the control group (p < 0.01). Arg inhibition resulted in a significant reduction of RVPsys to 52 ± 19 mmHg (p = 0.006) and histological sum-score to 5.8 ± 1.4 compared to the MCT group (p = 0.022). PH leads to increased expression of Arg. Arg inhibition leads to reduction of RVPsys and diminished lung tissue remodeling and therefore represents a potential treatment strategy in PH.

[1]  I. Petersen,et al.  Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression , 2016, Oncotarget.

[2]  A. Burnett,et al.  Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice , 2016, Anesthesia and analgesia.

[3]  N. Morrell,et al.  HIF2α–arginase axis is essential for the development of pulmonary hypertension , 2016, Proceedings of the National Academy of Sciences.

[4]  S. Waisbren,et al.  Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium , 2016, Journal of Inherited Metabolic Disease.

[5]  C. Jung,et al.  The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes. , 2016, Current vascular pharmacology.

[6]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[7]  L. Huber,et al.  The pathogenesis of pulmonary hypertension--an update. , 2015, Swiss medical weekly.

[8]  Bolin Sun,et al.  Arginase inhibition protects against hypoxia‑induced pulmonary arterial hypertension. , 2015, Molecular medicine reports.

[9]  E. Neufeld,et al.  Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia , 2015, British journal of haematology.

[10]  P. McNamara,et al.  Translational Research in Acute Lung Injury and Pulmonary Fibrosis Arginase inhibition prevents bleomycin-induced pulmonary hypertension , vascular remodeling , and collagen deposition in neonatal rat lungs , 2015 .

[11]  S. Erzurum,et al.  Arginine Metabolic Endotypes in Pulmonary Arterial Hypertension , 2015, Pulmonary circulation.

[12]  Sayoko Ogura,et al.  Pulmonary arterial hypertension in rats due to age-related arginase activation in intermittent hypoxia. , 2014, American journal of respiratory cell and molecular biology.

[13]  W. Qin,et al.  Arginase inhibitor attenuates pulmonary artery hypertension induced by hypoxia , 2015, Molecular and Cellular Biochemistry.

[14]  D. Badesch,et al.  [Definitions and diagnosis of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[15]  J. Dzik.  Evolutionary Roots of Arginase Expression and Regulation , 2014, Front. Immunol..

[16]  L. Nelin,et al.  Arginase II is a target of miR-17-5p and regulates miR-17-5p expression in human pulmonary artery smooth muscle cells. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[17]  L. Nelin,et al.  Asymmetric dimethylarginine does not inhibit arginase activity and is pro‐proliferative in pulmonary endothelial cells , 2014, Clinical and experimental pharmacology & physiology.

[18]  H. Meurs,et al.  Arginase Inhibition Prevents Inflammation and Remodeling in a Guinea Pig Model of Chronic Obstructive Pulmonary Disease , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[19]  H. Shim,et al.  Cervical Ganglion Block Attenuates the Progression of Pulmonary Hypertension via Nitric Oxide and Arginase Pathways , 2014, Hypertension.

[20]  C. Jung,et al.  Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? , 2013, Cardiovascular research.

[21]  W. Durante.  Role of Arginase in Vessel Wall Remodeling , 2013, Front. Immunol..

[22]  R. Homer,et al.  IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[23]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[24]  Xiaomei Meng,et al.  Pharmacologic agents elevating cAMP prevent arginase II expression and proliferation of pulmonary artery smooth muscle cells. , 2012, American journal of respiratory cell and molecular biology.

[25]  Sungyoung Choi,et al.  Immunohistochemical study of arginase 1 and 2 in various tissues of rats. , 2012, Acta histochemica.

[26]  L. Farkas,et al.  The monocrotaline model of pulmonary hypertension in perspective. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[27]  E. Block,et al.  Hypoxic upregulation of arginase II in human lung endothelial cells. , 2010, American journal of physiology. Cell physiology.

[28]  E. Block,et al.  Endothelial arginase II responds to pharmacological inhibition by elevation in protein level , 2010, Molecular and Cellular Biochemistry.

[29]  L. Nelin,et al.  Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. , 2010, American journal of physiology. Heart and circulatory physiology.

[30]  V. Kashyap,et al.  Thrombin induces endothelial arginase through AP-1 activation. , 2010, American journal of physiology. Cell physiology.

[31]  Inimary T. Toby,et al.  Hypoxia‐induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor (EGFR) tyrosine kinase activity , 2008, American journal of physiology. Lung cellular and molecular physiology.

[32]  L. Nelin,et al.  Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[33]  Kurt R Stenmark,et al.  Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[34]  Zhihong Yang,et al.  Endothelial arginase: A new target in atherosclerosis , 2006, Current hypertension reports.

[35]  N. Chesler,et al.  The Mechanobiology of Pulmonary Vascular Remodeling in the Congenital Absence of eNOS , 2006, Biomechanics and modeling in mechanobiology.

[36]  Stanley L Hazen,et al.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. , 2005, JAMA.

[37]  D. Christianson.  Arginase: structure, mechanism, and physiological role in male and female sexual arousal. , 2005, Accounts of chemical research.

[38]  J. Montani,et al.  Thrombin Stimulates Human Endothelial Arginase Enzymatic Activity via RhoA/ROCK Pathway: Implications for Atherosclerotic Endothelial Dysfunction , 2004, Circulation.

[39]  S. Hazen,et al.  Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[41]  Guoyao Wu,et al.  Activities of arginase I and II are limiting for endothelial cell proliferation. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[42]  W. Durante,et al.  Transforming Growth Factor-&bgr;1 Stimulates l-Arginine Transport and Metabolism in Vascular Smooth Muscle Cells: Role in Polyamine and Collagen Synthesis , 2001, Circulation.

[43]  W. Durante,et al.  Transforming growth factor-beta(1) stimulates L-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. , 2001, Circulation.

[44]  W. Durante,et al.  Physiological cyclic stretch directs L‐arginine transport and metabolism to collagen synthesis in vascular smooth muscle , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  L. Ignarro,et al.  IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. , 2000, American journal of physiology. Cell physiology.